GemVax
Financials
Valuation Metrics
GemVax's Market Cap is ₩5089B. At end of 2025 it was ₩1.3T. Ranked #481 of 2,419 in KR market (top 20%), #180 of 1,638 on KOSDAQ (top 11%), #67 of 214 in Semiconductors & Semiconductor Equipment (top 31%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 508.93B KRW | KR#481/2,419 Sec#67/214 |
| Revenue | 85.10B KRW | KR#1,513/2,419 Sec#130/214 |
| Net Income | -12.23B KRW | KR—/2,419 Sec—/214 |
| Total Assets | 163.11B KRW | KR#1,447/2,419 Sec#127/214 |
| Net Assets | 73.92B KRW | KR#1,637/2,419 Sec#141/214 |
| Employees | 199 | KR#1,112/2,419 Sec#101/214 |
| Value | ||
| P/B | 6.88x | KR#2,290/2,419 Sec#189/214 |
| P/S | 5.98x | KR#2,176/2,419 Sec#171/214 |
| EV/EBITDA | 66.71x | KR#1,405/2,419 Sec#110/214 |
| FCF Yield | 0.02% | KR#1,220/2,419 Sec#102/214 |
| Profitability | ||
| ROE | -16.54% | KR#2,051/2,419 Sec#181/214 |
| ROA | -7.50% | KR#2,037/2,419 Sec#177/214 |
| Op. Margin | 9.97% | KR#522/2,419 Sec#68/214 |
| Revenue Growth | 24.42% | KR#463/2,419 Sec#77/214 |
| Financial Health | ||
| Debt Ratio | 120.66% | KR#1,719/2,419 Sec#166/214 |
| Total Debt | 75.66B KRW | KR#832/2,419 Sec#55/214 |
| FCF | 111.3M KRW | KR#1,216/2,419 Sec#101/214 |
| Cash | 18.64B KRW | KR#1,283/2,419 Sec#126/214 |
| Current Ratio | 1.08x | KR#1,626/2,419 Sec#154/214 |
| Net Debt/EBITDA | 6.72x | KR#1,112/2,419 Sec#107/214 |
| Performance | ||
| 1Y Return | -77.93% | KR#2,346/2,419 Sec#210/214 |
| 1M Return | 7.80% | KR#639/2,419 Sec#138/214 |
| From 52W High | -81.66% | KR#2,355/2,419 Sec#212/214 |
| 1Y MDD | -84.50% | KR#2,353/2,419 Sec#211/214 |
| Trading | ||
| Volume | 88,525 shares | KR#875/2,419 Sec#124/214 |
| Trading Value | 985.6M KRW | KR#764/2,419 Sec#119/214 |
| Foreign Own. | 7.01% | KR#638/2,419 Sec#72/214 |
| Per Share | ||
| EPS | -269 KRW | KR—/2,419 Sec—/214 |
| BPS | 1,625 KRW | KR#2,164/2,419 Sec#192/214 |
Company Info
GemVax, established in 1998 for the manufacturing and sale of Coating Resin and filters, was listed on the KOSDAQ market in 2005. In its environmental pollution control division, the company specializes in localizing Chemical Filters for semiconductor and display applications, as well as providing air pollution prevention equipment. The bio division conducts clinical trials for diseases such as Alzheimer's using GV1001, simultaneously focusing on expanding overseas demand and researching next-generation peptide drugs. GemVax is headquartered in Seongnam City, Gyeonggi-do.